我武生物(300357) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the period reached CNY 225,662,001.09, a 35.14% increase year-on-year[8] - Net profit attributable to shareholders was CNY 116,103,579.65, reflecting a 35.96% increase compared to the same period last year[8] - Basic earnings per share rose by 35.93% to CNY 0.2217[8] - Total operating revenue for the current period reached ¥225,662,001.09, a 35% increase from ¥166,984,187.12 in the previous period[56] - Net profit for the current period was ¥114,131,251.78, representing a 34% increase compared to ¥85,187,635.57 in the previous period[59] - The total profit for the current period was ¥286,686,911.88, compared to ¥222,337,915.10 in the previous period, showing a growth of 28.9%[73] - The total comprehensive income for the current period was ¥242,829,112.44, compared to ¥189,144,518.54 in the previous period, reflecting a 28.4% increase[73] Assets and Liabilities - Total assets increased by 29.90% to CNY 1,374,187,040.89 compared to the end of the previous year[8] - Total liabilities increased to ¥72,157,419.36 from ¥62,471,999.59, marking a rise of about 11.5% year-over-year[42] - Total equity attributable to shareholders rose to ¥1,219,153,365.50 from ¥969,517,290.46, showing an increase of approximately 25.7%[45] - Total current assets increased to ¥1,027,821,517.98 from ¥781,658,393.23, representing a growth of approximately 31.5% year-over-year[39] - Non-current assets totaled ¥346,365,522.91, up from ¥276,234,115.45, indicating a year-over-year increase of about 25.4%[39] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 157,551,183.19, an increase of 19.01%[8] - Net cash flow from financing activities increased by 128,420,000.00 yuan, a rise of 198.67%, primarily due to increased cash from minority shareholders' investments in subsidiaries[24] - Cash and cash equivalents increased to ¥394,333,616.27 from ¥317,219,365.02, representing a growth of about 24.3%[46] - Cash flow from operating activities generated ¥157,551,183.19, compared to ¥132,382,655.68 in the same period last year[81] - The company received cash inflows from investment activities totaling ¥264,912,984.10, down from ¥647,084,171.25 in the previous year[82] Shareholder Information - The total number of shareholders at the end of the reporting period was 14,676[12] - The largest shareholder, Zhejiang Wo Wu Management Consulting Co., Ltd., holds 38.86% of the shares[12] Research and Development - R&D expenses surged by 17,120,795.59 yuan, a significant increase of 189.47%, due to higher material consumption and salaries in the stem cell subsidiary[23] - Research and development expenses rose significantly to ¥12,102,332.46, up from ¥3,253,633.11 in the previous period, indicating a focus on innovation[56] - Research and development expenses for the current period amounted to ¥26,156,958.32, significantly higher than ¥9,036,162.73 in the previous period, marking a 189.5% increase[69] Government Support - The company received government subsidies amounting to CNY 3,505,769.64 during the reporting period[8] Other Financial Metrics - The weighted average return on equity was 10.00%, a slight increase of 0.33%[8] - The company reported a financial asset impairment loss of ¥3,368,948.21, compared to a loss of ¥2,192,490.79 in the previous period[63] - Other comprehensive income after tax for the current period was ¥8,154.10, down from ¥13,968.79 in the previous period[62] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[61]